IL2 and type 1 diabetes mellitus: Although β-cell-specific IL-2 demonstrated efficacy comparable to systemic IL-2 in preventing T1D, these data suggest that a β-cell-targeted strategy may exhibit advantage for effectively sustaining the functional capacity of intra-islet Tregs within the context of T1D.